SCHEMBL5871960

SCHEMBL5871960

O=c1c([I+]c2ccccc2)c([O-])c2cccnc2n1Cc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.45
CNR2 P34972 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
PTGDR2 Q9Y5Y4 1/20 0.45
HDAC1 Q13547 1/20 0.44
HDAC11 Q96DB2 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
PDE4A P27815 2/20 0.44
PDE4B Q07343 2/20 0.44
PDE4C Q08493 2/20 0.44
PDE4D Q08499 2/20 0.44
RXFP1 Q9HBX9 2/20 0.44
MAPT P10636 4/20 0.42
TP53 P04637 1/20 0.42
KAT2B Q92831 1/20 0.41
THRB P10828 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5872204 0.90 MAPT (0.53) MEN1KMT2APTGDR2RXFP1MAPT
SCHEMBL7945856 0.88 HDAC1 (0.48) MEN1KMT2AHDAC1HDAC11HDAC8
SCHEMBL5872307 0.87 CCNA2 (0.39) MEN1KMT2APTGDR2PDE4APDE4B
SCHEMBL5871439 0.85 LIPG (0.43) MEN1KMT2ARXFP1MAPTTHRB
SCHEMBL7945833 0.85 L3MBTL1 (0.51) RXFP1MAPTTP53THRB
SCHEMBL5872030 0.85 PDE4D (0.43) CNR1CNR2MEN1KMT2APDE4A
SCHEMBL5872145 0.82 ALDH1A1 (0.41) MEN1KMT2APTGDR2PDE4APDE4B
SCHEMBL5871920 0.80 FEN1 (0.45) PDE4APDE4BPDE4CPDE4D
SCHEMBL5871709 0.79 FEN1 (0.50) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL5872001 0.74 GAA (0.42) CNR1CNR2MEN1KMT2APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7071187-B2 Naphthyridine derivatives OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2006-07-04 US disclosed
US-20040214853-A1 Naphthyridine derivatives OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2004-10-28 US disclosed
EP-1426374-A1 NAPHTHYRIDINE DERIVATIVE OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2004-06-09 EP disclosed
US-6245779-B1 ANALGESICS; ANTIINFLAMMATORY AGENTS OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2001-06-12 US disclosed
EP-0997463-A1 NAPHTHYRIDINE DERIVATIVES OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2000-05-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040214853-A1 Naphthyridine derivatives MT-ND1, OPRD1, NR0B1 CNR1 81/4885CNR2 231/4885MEN1 3746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.